With a selection of more than fifty works, including tapestries, paintings, sculptures, photographs and clocks, the exhibition La tiranía de Cronos is an inquiry into the idea of time and its ...

Joshua Short is a 4-time Emmy Award-winning broadcast journalist, from Chicago, Illinois. Not far from where he was raised in the Windy City is where he grew up professionally. He moved to the ...

As KUOW's Growth and Development reporter and co-host of KUOW's Booming podcast, Joshua's "growing pains" beat sits at the nexus of housing, transportation, urban planning, government and the economy.

Joshua Tree National Park is often described as an out-of-this-world experience or healing for one’s soul, says Donovan Smith, the park’s public information officer. “With blue sunny skies ...

Joshua Rhett Miller is a Newsweek chief investigative reporter based in New York. His areas of focus include U.S. politics, immigration and society, as well as crime, education and technology.

Joshua Barajas is a senior editor for the PBS NewsHour's Communities Initiative. He's also the senior editor and manager of newsletters. He can be reached at [email protected]. “These ...

June 4, 2025 • The Met's spring exhibition presents a cultural and historical examination of Black style over 300 years through the concept of dandyism. May 28, 2025 • What does it mean to be ...

After completing his studies at the American Academy of Art in Chicago, Elvgren worked for several advertising agencies before becoming a freelance artist in the late 1930s. His work quickly gained ...

Davies-Okundaye’s works have been showcased in global exhibitions, solidifying her influence in the art world. Her peers include Tola Wewe, a Nigerian sculptor known for his innovative use of ...

Meanwhile, GSK's chief commercial officer Luke Miels said that tebipenem "complements GSK’s infectious disease strategy and is consistent with our commitment to find value-enhancing ...

GSK's chief commercial officer Luke Miels said on the company's second-quarter results call earlier this week that Jemperli "is the backbone of our immuno-oncology development, and pending ...